Acute promyelocytic leukemia (APL) is associated with chromosomal translocations involving RAR and its fusion partners including PML and PLZF. Using oligonucleotide arrays, we examined changes in global gene expression mediated by the ectopic expression of either PML/RAR (retinoid-sensitive) or PLZF/RAR (retinoid-resistant) in U937 cells. Of over 5000 genes analyzed, 16 genes were commonly upregulated, and 57 genes were downregulated by both fusion proteins suggesting their role in the APL phenotype. In our APL model, for example, TNFAIP2, TNFR2, ELF4, RAR , and HoxA1 were downregulated by both fusion proteins in the absence of RA. RA strongly upregulated these genes in PML/RAR , but not in PLZF/RAR expressing U937 cells. Expression studies in NB4, retinoid-resistant NB4-R2, normal human 3
Introduction
Acute promyelocytic leukemia (APL) is characterized by a unique translocation involving the retinoic acid receptor (RAR ) and one of its fusion partners, promyelocytic leukemia (PML), promyelocytic leukemia zinc finger (PLZF), nucleophosmin (NPM), Nuclear Matrix Associated (NuMA), and signal transducer and activator of transcription 5B (STAT5B). 1, 2 The majority of APL cases are caused by PML/RAR that retains most of the putative functional domains of PML and the DNA and ligand-binding domains of RAR .
PML/RAR can heterodimerize with RXR and PML, and thus has the potential to interfere with the endogenous signaling pathways of both PML and RAR , thereby promoting cell growth by blocking apoptotic cell death and inhibiting terminal differentiation of hematopoietic precursor cells. Recently, all-trans retinoic acid (ATRA) has become a standard therapy for the induction of remissions in patients with APL caused by PML/RAR . 3 APL provides an excellent model in which a specific abnormal gene product is responsible both for the APL phenotype and for the in vitro and in vivo sensitivity to cell differentiation mediated by ATRA.
In contrast, a small subset of patients with APL develop leukemia as a result of t (11;17) causing a PLZF/RAR fusion protein. 4, 5 This APL is morphologically indistinguishable from that caused by PML/RAR but is usually unresponsive to retinoids. PLZF/RAR has a retinoidindependent corepressor-binding domain in the amino terminus (POZ domain) of PLZF, which may be the cause for retinoid resistance of these APL cells both in vivo and in vitro. 6 Current understanding of APL pathogenesis suggests that the aberrant fusion proteins, PML/RAR , PLZF/RAR , and others, recruit co-repressors and histone deacetylases (HDACs) to their putative target genes in the absence of pharmacologic levels of retinoic acids, and these APL fusion proteins share downstream target genes and signaling pathways. 7, 8 However, what these are, remain largely unknown. The above hypothesis suggests that APL fusion proteins will repress the expression of these target genes in the absence of retinoids. Whether these fusion proteins have other mechanisms of action by upregulating target gene expression is not known.
Furthermore, molecular pathways that are involved in RA responsiveness and resistance in APL are poorly understood. Recent developments in DNA microarray technologies enable us to look at the changes in global gene expression that are associated with a single gene abnormality. 9, 10 In this report, using similar approaches, we show global gene expression profiles of retinoidsensitive and -resistant APL and retinoid treatment effects in a cell line model. In addition, using this approach, we identified new sets of genes that may be important in APL pathogenesis as well as retinoid responsiveness or resistance in APL. We show that comparative gene expression analysis can be utilized in identifying potential molecular targets for the development of novel therapeutics. RNA from each sample was used to prepare biotinylated cRNA probes, and 15 µg of labeled cRNA from each sample was used for hybridization to HuGeneFL Array (Affymetrix, Inc., Santa Clara, CA) at the GeneChip Core, University of California, San Diego as described previously. 16 Following the hybridization, arrays were washed and stained with streptavidin -phycoerythrin and scanned on a Hewlett Packard scanner. The measured fluorescence intensity values were captured using GeneChip software (Affymetrix), and the data were normalized by global scaling to a target value of 2500 and to the average fluorescence intensity for the entire microarray.
Methods
Microarray data analysis. Data generated by GeneChip software (Affymetrix) were exported to GeneSpring software version 4.2 (Silicon Genetics, Inc., San Carlos, CA) for further analyses. For hierarchical clustering analysis (Figure 1 ), GeneChip software generated data sets were entered as 18 independent experiments (6 experimental groups in triplicate) into
GeneSpring software, and Experiment Normalization was used to standardize the microarray data. Following standardization, data sets were subjected to a Statistical Group Comparison filter in order to test for significant differences in expression levels between experimental groups. A non-parametric (Kruskal-Wallis) test with a p-value cutoff of 0.001 was applied to generate a list of genes that can best differentiate various experimental groups. Gene and experiment trees were generated using this gene list; similarities were measured by Spearman correlation (separation ratio 0.5; minimum distance 0.001). (Tables 1 and 2 ).
Northern blot analysis. Microarray data were confirmed by Northern blot analysis using the same total RNA samples that were used in the microarray analysis or total RNA isolated from NB4 or NB4-R2 cells that were treated with ATRA (1 µM). For transcriptional regulation experiments, U937PR9 cells were pretreated either with or without cycloheximide (CHX) (10 µg/ml; Sigma) for 30 minutes to inhibit new protein synthesis, and then the cells were induced with ATRA (1 µM) for six hours. Northern blot analyses were carried out using 10 µg of total RNA as described previously.
15
Reverse transcriptase-polymerase chain reaction (RT-PCR). CD34 + cells from bone marrow of normal volunteers were isolated and differentiated as described previously. 17 Cells were harvested on days 0, 2, 5, 7, 9, and 12 days for total RNA. Semi-quantitative RT -PCR for retinoid-regulated genes or CD34, CD11b, and lactoferrin was performed using RNA samples made from three independent cultures using standard methods. 17 In addition, RT-PCR for 18S
was utilized as an internal control to ensure equal loading of samples. Cell differentiation and apoptosis analysis. NB4 and NB4-R2 cells were cultured in media containing ATRA (0.1 µM) alone, tumor necrosis factor (TNF ) (10 ng/ml; Sigma) alone, or ATRA plus TNF for 7 days; cells were then harvested at 0, 2, 4, and 7 days.
Differentiation and apoptosis using markers, CD66b and Annexin V, respectively, were assessed by FACS as previously described. 15 All analyses were carried out in triplicate, and the mean percentage of cells with positive expression and standard deviations were calculated. Genes that are involved in the pathogenesis of APL. Genes that were commonly regulated by the expression of either PML/RAR or PLZF/RAR fusion proteins were examined in a pair-wise comparisons in triplicate experiments ( Figure 2A ). The number of genes that were either down-or up-regulated at least two-fold and had a raw intensity value of at least 1000 in the experimental sample in each of the three independent experiments are represented in Venn diagrams. From our experience, these restrictions were good at predicting significant gene expression differences on subsequent Northern blot analyses, and triplicate experiments were critical to ensure that variabilities between experiments do not affect our outcome analysis. 57 genes were commonly downregulated by both fusion proteins in all three experiments, whereas 37 and 31 genes were down-regulated by either PML/RAR or PLZF/RAR alone, respectively.
Results

Analysis
In addition, we found that 16 genes were commonly upregulated by both fusion proteins in all three experiments, whereas 16 and 37 genes were upregulated by only PML/RAR or PLZF/RAR , respectively. A list of the commonly down-or up-regulated genes is shown in Table 1 . The number of commonly down-regulated genes is substantially greater than the number of commonly up-regulated genes; this result affirms the notion that these fusion genes mainly function as transcriptional repressors. Table 2 . A subset of genes that were commonly downregulated by both fusion proteins was uniquely upregulated by RA only in the PML/RAR (retinoid sensitive) expressing cells. For example, the expression of the ELF4, TNFR2, TNFAIP2, and RAR genes were strongly downregulated by the APL fusion proteins in the absence of RA. However, these genes were specifically upregulated in the presence of RA only in the PML/RAR expressing cells but not in those expressing either PLZF/RAR or the parental U937 cells ( Figure 3B ).
These genes were direct transcriptional targets of RA since new protein synthesis was not required for the retinoid-induced upregulation ( Figure 3B ). LSP1, IL8, and homeobox A1 (HoxA1) were also upregulated by RA ( Figure 3B ). While induction of HoxA1 expression was independent of new protein synthesis, LSP1 and IL8 were not direct transcriptional targets of RA as indicated by cycloheximide experiments (data not shown). In addition, the expression of the anti-apoptotic gene BCL2 was strongly upregulated by the APL fusion proteins in the absence of RA. However, in response to RA, BCL2 expression was downregulated in PML/RAR expressing cells but not in PLZF/RAR expressing or parental U937 cells ( Figure 3B ).
In order to confirm that retinoid regulation of these genes was not specific to U937PR9 cells, the retinoid responsiveness of ELF4, TNFR2, TNFAIP2, RAR , HoxA1, and BCL2 gene expression was also examined in the APL cell line NB4 and the retinoid-resistant NB4-R2 cells.
ELF4, an E74 family member of the Ets-related transcription factors was upregulated during retinoid-induced granulocytic differentiation of NB4 and HL60 cells but not in retinoid-resistant NB4-R2 cells ( Figure 4A and data not shown). Similarly, the expression of TNFAIP2 and 
Discussion
The idea that aberrant fusion proteins such as PML/RAR and PLZF/RAR cause the development of APL is well known. However, the target genes and pathways altered by these fusion proteins have not been examined systematically. In addition, target genes of PML/RAR and PLZF/RAR that determine either retinoid sensitivity or resistance are largely unknown.
The development of microarray technology enables us to examine the global gene expression profiles of the APL model system.
Our study was performed in a homogeneous cell population, the AML cell line U937. We (Table 1) .
Common molecular targets of the APL fusion proteins are responsible for the phenotype of APL.
Interestingly, expression of primary granule genes, such as ELA2, LYZ, PRTN3, and MPO, was similarly regulated by both fusion proteins. The design of our study does not permit us to evaluate whether the fusion proteins transcriptionally regulate these target genes. It is possible that these changes are secondary to expression of the APL fusion proteins.
In our APL model, we have identified several interesting apoptosis-related genes targeted by retinoic acid including TNFAIP2, TNFR2, and BCL2. TNFAIP2 (B94) was originally cloned as a TNF induced gene in human endothelial cells, 20 but subsequent studies identified its expression in hematopoietic tissues and reported that it was inducible by retinoic acid in PML/RAR expressing TF-1 and NB4 cells. 21, 22 Our study is consistent with a potential role for TNFAIP2 in APL.
Here has putative roles in secretion of GM-CSF by T lymphocytes and myeloid differentiation. 26, 27 Confirmation of our data on APL patient samples further strengthens potential applicability of our results to clinical situations. Interestingly, combined treatment with RA and TNF synergistically enhanced granulocytic differentiation in NB4 but not in NB4-R2 cells suggesting cooperation between RA and TNF signaling pathways ( Figure 5C) . In contrast, level of apoptosis with combined treatment was not significantly changed between different treatment groups ( Figure 5D ). These results are consistent with findings from prior studies that TNF may promote granulocytic differentiation in CD34 + cord blood cells. 28 Our study suggests that regulation of differentiation and apoptosis are closely linked and therapeutically targeting both pathways may be helpful in the treatment of APL.
ELF4 is a member of the E74 family of ETS proteins also known as myeloid elf-1 like factor (MEF). ELF4 binds to ETS binding sites in the GM -CSF and IL-3 promoters augmenting their transactivation. 29, 30 Furthermore, ELF4 and AML1b synergistically transactivate the IL-3 promoter, suggesting a role for ELF4 in regulation of myeloid differentiation. AML1/ETO dominantly represses the transactivating activity of ELF4. Repression of ELF4 expression by both APL fusion proteins observed in this study as well as by AML1/ETO suggests the importance of dysregulation of ELF4 expression in both types of AML.
In a "two-hit" model of leukemogenesis, 31 *Probability of a false positive on individual genes using Student's t-test is reported as p values. **Mean fold changes were calculated using a simple division of raw expression values between experimental sample and control. Triplicate experiments were performed in a paired fashion at three different times. Northern blot analysis using the same samples of total RNA used in the microarray analysis confirmed the RA regulation of genes from microarray data.
In addition, effect of protein synthesis inhibitor, cycloheximide (CHX) on retinoid-dependent gene expression was examined. U937PR9 cells were incubated with CHX (10 µg/ml) alone, CHX and ATRA (10 -6 M), or ATRA alone for 0 and 6 hours. Each blot was rehybridized for GAPDH to assure equal loading of RNA. Control RT-PCR reactions were performed for differentiation marker genes, such as CD34, CD11b, and lactoferrin. In addition, RT-PCR for 18S was carried out as an internal control to ensure equal loading of the samples. 
